ArticleThe Journal of physiology2026
Structural determinants of quadriceps atrophy following ACL injury: Evidence for fibre atrophy without fibre loss or overt peripheral denervation.
Article in The Journal of physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Quadriceps atrophy is a well-established consequence of anterior cruciate ligament (ACL) injury, yet the mechanisms driving this process remain poorly characterized. Specifically, it is unclear whether atrophy reflects decreases in fibre cross-sectional area (CSA) or fibre number, and whether the neural inhibition accompanying ACL injury extends to peripheral neuromuscular junctions (NMJs). Using a rat model of non-invasive ACL injury and whole-muscle histological analysis, we quantified changes in vastus lateralis fibre CSA, fibre number, fibre-type distribution, and NMJ integrity and function at early post-injury timepoints. By 7 days post-injury, fibre CSA was significantly reduced in both sexes across all Type II subtypes, with deficits persisting at 14 days. Total fibre number was maintained, demonstrating that whole-muscle atrophy is driven primarily by reductions in fibre CSA rather than fibre loss. At 3 days post-injury, no significant difference in NMJ innervation and compound muscle action potential amplitude were observed, suggesting that early atrophy is not preceded by peripheral denervation. Reductions in electromyographic amplitude and stance duration during treadmill walking indicated decreased muscle activation and limb loading following injury. Shifts in fibre-type distribution to IIb were also observed. This work clarifies the structural basis of early quadriceps atrophy following ACL injury, demonstrating that quadriceps atrophy is likely not preceded by peripheral denervation and is characterized primarily by reductions in fibre CSA. These findings support rehabilitation strategies that target fibre growth, but the persistent nature of quadriceps atrophy in patients suggests that current approaches may be insufficient and require further optimization. KEY POINTS: Anterior cruciate ligament (ACL) injury results in persistent quadriceps atrophy, yet whether deficits in whole-muscle size result from reductions in fibre cross-sectional area or number, and whether the integrity of neuromuscular junctions is impaired, remains unclear. Using a rat model of ACL injury and whole-muscle histology, we demonstrate that quadriceps atrophy is driven by decreased fibre cross-sectional area, not fibre loss, and that this affects all Type II subtypes. Quadriceps neuromuscular junctions remained structurally and functionally intact, demonstrating that early quadriceps atrophy is not preceded by denervation. Shifts in fibre-type composition toward a more glycolytic phenotype were observed, consistent with patterns reported in models of muscle unloading and disuse. By identifying fibre-level atrophy without fibre loss, these findings highlight a key therapeutic target and support strategies that target fibre growth to address the persistent atrophy that plagues ACL-injured patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.